Selected research
Market Structure
Global Activin Receptor Type 1 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Activin Receptor Type 1 market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Activin Receptor Type 1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Activin Receptor Type 1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Activin Receptor Type 1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Activin Receptor Type 1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Activin Receptor Type 1 include Tolero Pharmaceuticals Inc, Oncodesign SA, La Jolla Pharmaceutical Company, Daiichi Sankyo Company Ltd and Blueprint Medicines Corp, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Activin Receptor Type 1 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Activin Receptor Type 1 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Activin Receptor Type 1 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Activin Receptor Type 1 market size, projected growth trends, production technologies, key applications, and end-use industries.
Activin Receptor Type 1 Segment by Company
Tolero Pharmaceuticals Inc
Oncodesign SA
La Jolla Pharmaceutical Company
Daiichi Sankyo Company Ltd
Blueprint Medicines Corp
Activin Receptor Type 1 Segment by Type
LJPC-6417
Dipyridamole
TP-0184
Others
Activin Receptor Type 1 Segment by Application
Alport Syndrome
Kidney Fibrosis
Chronic Kidney Disease
Obesity
Others
Activin Receptor Type 1 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Activin Receptor Type 1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Activin Receptor Type 1 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Activin Receptor Type 1.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Activin Receptor Type 1 market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Activin Receptor Type 1 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Activin Receptor Type 1 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Activin Receptor Type 1 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- LJPC-6417
- Dipyridamole
- TP-0184
- Others
Applications
- Alport Syndrome
- Kidney Fibrosis
- Chronic Kidney Disease
- Obesity
- Others
Companies covered
- Tolero Pharmaceuticals Inc
- Oncodesign SA
- La Jolla Pharmaceutical Company
- Daiichi Sankyo Company Ltd
- Blueprint Medicines Corp
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Activin Receptor Type 1 Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Activin Receptor Type 1 Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Activin Receptor Type 1 Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Activin Receptor Type 1 Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Activin Receptor Type 1 Market Dynamics
- 2.1 Activin Receptor Type 1 Industry Trends
- 2.2 Activin Receptor Type 1 Industry Drivers
- 2.3 Activin Receptor Type 1 Industry Opportunities and Challenges
- 2.4 Activin Receptor Type 1 Industry Restraints
3 Activin Receptor Type 1 Market by Manufacturers
- 3.1 Global Activin Receptor Type 1 Revenue by Manufacturers (2021-2026)
- 3.2 Global Activin Receptor Type 1 Sales by Manufacturers (2021-2026)
- 3.3 Global Activin Receptor Type 1 Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Activin Receptor Type 1 Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Activin Receptor Type 1 Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Activin Receptor Type 1 Manufacturers, Product Type & Application
- 3.7 Global Activin Receptor Type 1 Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Activin Receptor Type 1 Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Activin Receptor Type 1 Players Market Share by Revenue in 2025
- 3.8.3 2025 Activin Receptor Type 1 Tier 1, Tier 2, and Tier 3
4 Activin Receptor Type 1 Market by Type
- 4.1 Activin Receptor Type 1 Type Introduction
- 4.1.1 LJPC-6417
- 4.1.2 Dipyridamole
- 4.1.3 TP-0184
- 4.1.4 Others
- 4.2 Global Activin Receptor Type 1 Sales by Type
- 4.2.1 Global Activin Receptor Type 1 Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Activin Receptor Type 1 Sales by Type (2021-2032)
- 4.2.3 Global Activin Receptor Type 1 Sales Market Share by Type (2021-2032)
- 4.3 Global Activin Receptor Type 1 Revenue by Type
- 4.3.1 Global Activin Receptor Type 1 Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Activin Receptor Type 1 Revenue by Type (2021-2032)
- 4.3.3 Global Activin Receptor Type 1 Revenue Market Share by Type (2021-2032)
5 Activin Receptor Type 1 Market by Application
- 5.1 Activin Receptor Type 1 Application Introduction
- 5.1.1 Alport Syndrome
- 5.1.2 Kidney Fibrosis
- 5.1.3 Chronic Kidney Disease
- 5.1.4 Obesity
- 5.1.5 Others
- 5.2 Global Activin Receptor Type 1 Sales by Application
- 5.2.1 Global Activin Receptor Type 1 Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Activin Receptor Type 1 Sales by Application (2021-2032)
- 5.2.3 Global Activin Receptor Type 1 Sales Market Share by Application (2021-2032)
- 5.3 Global Activin Receptor Type 1 Revenue by Application
- 5.3.1 Global Activin Receptor Type 1 Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Activin Receptor Type 1 Revenue by Application (2021-2032)
- 5.3.3 Global Activin Receptor Type 1 Revenue Market Share by Application (2021-2032)
6 Global Activin Receptor Type 1 Sales by Region
- 6.1 Global Activin Receptor Type 1 Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Activin Receptor Type 1 Sales by Region (2021-2032)
- 6.2.1 Global Activin Receptor Type 1 Sales by Region (2021-2026)
- 6.2.2 Global Activin Receptor Type 1 Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Activin Receptor Type 1 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Activin Receptor Type 1 Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Activin Receptor Type 1 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Activin Receptor Type 1 Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Activin Receptor Type 1 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Activin Receptor Type 1 Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Activin Receptor Type 1 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Activin Receptor Type 1 Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Activin Receptor Type 1 Revenue by Region
- 7.1 Global Activin Receptor Type 1 Revenue by Region
- 7.1.1 Global Activin Receptor Type 1 Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Activin Receptor Type 1 Revenue by Region (2021-2026)
- 7.1.3 Global Activin Receptor Type 1 Revenue by Region (2027-2032)
- 7.1.4 Global Activin Receptor Type 1 Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Activin Receptor Type 1 Revenue (2021-2032)
- 7.2.2 North America Activin Receptor Type 1 Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Activin Receptor Type 1 Revenue (2021-2032)
- 7.3.2 Europe Activin Receptor Type 1 Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Activin Receptor Type 1 Revenue (2021-2032)
- 7.4.2 Asia-Pacific Activin Receptor Type 1 Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Activin Receptor Type 1 Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Activin Receptor Type 1 Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Tolero Pharmaceuticals Inc
- 8.1.1 Tolero Pharmaceuticals Inc Company Information
- 8.1.2 Tolero Pharmaceuticals Inc Business Overview
- 8.1.3 Tolero Pharmaceuticals Inc Activin Receptor Type 1 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Tolero Pharmaceuticals Inc Activin Receptor Type 1 Product Portfolio
- 8.1.5 Tolero Pharmaceuticals Inc Recent Developments
- 8.2 Oncodesign SA
- 8.2.1 Oncodesign SA Company Information
- 8.2.2 Oncodesign SA Business Overview
- 8.2.3 Oncodesign SA Activin Receptor Type 1 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Oncodesign SA Activin Receptor Type 1 Product Portfolio
- 8.2.5 Oncodesign SA Recent Developments
- 8.3 La Jolla Pharmaceutical Company
- 8.3.1 La Jolla Pharmaceutical Company Company Information
- 8.3.2 La Jolla Pharmaceutical Company Business Overview
- 8.3.3 La Jolla Pharmaceutical Company Activin Receptor Type 1 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 La Jolla Pharmaceutical Company Activin Receptor Type 1 Product Portfolio
- 8.3.5 La Jolla Pharmaceutical Company Recent Developments
- 8.4 Daiichi Sankyo Company Ltd
- 8.4.1 Daiichi Sankyo Company Ltd Company Information
- 8.4.2 Daiichi Sankyo Company Ltd Business Overview
- 8.4.3 Daiichi Sankyo Company Ltd Activin Receptor Type 1 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Daiichi Sankyo Company Ltd Activin Receptor Type 1 Product Portfolio
- 8.4.5 Daiichi Sankyo Company Ltd Recent Developments
- 8.5 Blueprint Medicines Corp
- 8.5.1 Blueprint Medicines Corp Company Information
- 8.5.2 Blueprint Medicines Corp Business Overview
- 8.5.3 Blueprint Medicines Corp Activin Receptor Type 1 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Blueprint Medicines Corp Activin Receptor Type 1 Product Portfolio
- 8.5.5 Blueprint Medicines Corp Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Activin Receptor Type 1 Value Chain Analysis
- 9.1.1 Activin Receptor Type 1 Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Activin Receptor Type 1 Production Mode & Process
- 9.2 Activin Receptor Type 1 Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Activin Receptor Type 1 Distributors
- 9.2.3 Activin Receptor Type 1 Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst